RTW — RTW Biotech Opportunities Income Statement
0.000.00%
Last trade - 00:00- $407.19m
- $496.98m
- $8.19m
Annual income statement for RTW Biotech Opportunities, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.154 | 0.658 | 2.17 | 4.17 | 8.19 |
| Cost of Revenue | |||||
| Gross Profit | -4.43 | -7.24 | -4.76 | -3.9 | -7.59 |
| Selling / General / Administrative Expenses | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.11 | 8.45 | 7.46 | 8.93 | 16.9 |
| Operating Profit | -4.95 | -7.8 | -5.29 | -4.76 | -8.74 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 161 | -64.3 | -39.4 | 83.2 | 34.2 |
| Net Income After Taxes | 161 | -64.3 | -39.4 | 83.2 | 34.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 161 | -64.3 | -39.4 | 83.2 | 34.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 161 | -64.3 | -39.4 | 83.2 | 34.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.839 | -0.303 | -0.186 | 0.395 | 0.102 |